附録

検索式

本ガイドライン第4 版では,全てのCQ・BQ における文献検索を日本医学図書館協会に依頼した。

1 画像診断領域

画像1(BQ)  GIST が疑われる患者の確定診断にEUS-FNA は有用か

PubMed

検索日:2018 年3 月21 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH] 1,932
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(diagnos[TIAB]OR detect[TIAB]OR screening[TIAB]) 3,821
#03 “Endoscopic Ultrasound‒Guided Fine Needle Aspiration”[MH] 1,651
#04 Endoscopic Ultrasound Guided Fine Needle Aspiration[TIAB]OR EUS‒FNA[TIAB] 2,278
#05 (#1 OR #2)AND(#3 OR #4) 124
#06 #5 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH] OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 3
#07 #5 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB]) 5
#08 #5 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 7
#09 (#7 OR #8)NOT #6 9
#10 #5 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 82
#11 #10 NOT(#6 OR #9) 74

Cochrane Library

検索日:2018 年3 月21 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 Endoscopic Ultrasound Guided Fine Needle Aspiration:ti,ab,kw OR EUS‒FNA:ti,ab,kw 299
#03 #1 and #2 20
#04 #3 CDSR 0
#05 #3 CCRCT 20

画像2(BQ)  GIST 患者の病期診断や再発診断にCT,MRI は有用か

PubMed

検索日:2018 年3 月21 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH] 1,932
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(diagnos[TIAB]OR detect[TIAB]OR screening[TIAB]) 3,821
#03 “Tomography, X‒Ray Computed”[MH]OR “Magnetic Resonance Imaging”[MH] 693,548
#04 “Computed Tomography”[TIAB]OR “Computed X Ray Tomography”[TIAB]OR “Computer Assisted Tomography”[TIAB]OR “Computerized Tomography”[TIAB]OR CT X Ray[TIAB]OR Tomodensitometry[TIAB]OR X‒Ray CAT Scan[TIAB]OR X‒Ray CT Scan[TIAB]OR Cine CT[TIAB]OR “Electron Beam Tomography”[TIAB]OR “X Ray Computerized Axial Tomography”[TIAB]OR Magnetic Resonance Imaging[TIAB]OR “NMR Imaging”[TIAB]OR “MR Tomography”[TIAB]OR “NMR Tomography”[TIAB]OR MRI[MR[I TIAB]TIAB]OR Zeugmatography[TIAB]OR Chemical Shift Imaging[TIAB]OR “Proton Spin Tomography”[TIAB]OR “Magnetization Transfer Contrast Imaging”[TIAB]OR MRI Scan[TIAB]OR fMRI[TIAB]OR Functional MRI[TIAB]OR Spin Echo Imaging[TIAB] 521,916
#05 “Neoplasm Staging”[MH]OR “Neoplasm Recurrence, Local”[MH]OR “Recurrence”[MH] 403,579
#06 Neoplasm Staging[TIAB]OR Tumor Staging[TIAB]OR Cancer Staging[TIAB]OR TNM Staging[TIAB]OR TNM Classification[TIAB]OR timing[TIAB]OR recurren[TIAB] 595,342
#07 (#1 OR #2)AND(#3 OR #4)AND(#5 OR #6) 271
#08 #7 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 8
#09 #7 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 7
#10 #7 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 15
#11 (#9 OR #10)NOT #8 15
#12 #7 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 192
#13 #12 NOT(#8 OR #11) 173

Cochrane Library

検索日:2018 年3 月21 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 “Computed Tomography”:ti,ab,kw or “Computed X Ray Tomography”:ti,ab,kw or “Computer Assisted Tomography”: ti, ab, kw or “Computerized Tomography”:ti,ab,kw or “CT X Ray”:ti,ab,kw or Tomodensitometry:ti,ab,kw or “X‒Ray CAT Scan”:ti,ab,kw or “X‒Ray CT Scan”:ti,ab,kw or “Cine CT”:ti,ab,kw or “Electron Beam Tomography”:ti,ab,kw or “X Ray Computerized Axial Tomography”:ti,ab,kw or “Magnetic Resonance Imaging”:ti,ab,kw or “NMR Imaging”:ti,ab,kw or “MR Tomography”:ti,ab,kw or “NMR Tomography”:ti,ab,kw or MRI:ti,ab,kw or Zeugmatography:ti,ab,kw or “Chemical Shift Imaging”:ti,ab,kw or “Proton Spin Tomography”:ti,ab,kw or “Magnetization Transfer Contrast Imaging”:ti,ab,kw or “MRI Scan”:ti,ab,kw or fMRI:ti,ab,kw or “Functional MRI”:ti,ab,kw or “Spin Echo Imaging”:ti,ab,kw 29,314
#03 Neoplasm Staging:ti,ab,kw OR Tumor Staging:ti,ab,kw OR Cancer Staging: ti,ab,kw OR TNM Staging:ti,ab,kw OR TNM Classification:ti,ab,kw OR timing: ti,ab,kw OR recurren:ti,ab,kw 92,874
#04 #1 and #2 and #3 11
#05 #4 CDSR 0
#06 #4 CCRCT 11

画像3(BQ)  GIST 患者の病期診断や再発診断にFDG-PET/CT は有用か

PubMed

検索日:2018 年3 月21 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH] 1,932
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(diagnos[TW]OR detect[TW]OR screening[TW]) 4,948
#03 “Positron Emission Tomography Computed Tomography”[MH]AND “Fluorodeoxyglucose F18”[MH] 1,524
#04 ((Fluorodeoxyglucose[TIAB]OR FDG[TIAB])AND(Positron Emission Tomography Computed Tomograph[TIAB]OR Positron Emission Tomography CT[TIAB]OR PET computed tomograph[TIAB]OR PET CT[TIAB]OR CT PET[TIAB]OR PET scan[TIAB]OR PET imaging[TIAB]))OR FDG PET[TIAB] 25,372
#05 “Neoplasm Staging”[MH]OR “Neoplasm Recurrence, Local”[MH]OR “Recurrence”[MH] 403,579
#06 Neoplasm Staging[TIAB]OR Tumor Staging[TIAB]OR Cancer Staging[TIAB]OR TNM Staging[TIAB]OR TNM Classification[TIAB]OR timing[TIAB]OR recurren[TIAB] 595,342
#07 (#1 OR #2)AND(#3 OR #4)AND(#5 OR #6) 41
#08 (#1 OR #2)AND(#3 OR #4) 143
#09 #8 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 6
#10 #8 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 5
#11 #8 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 21
#12 (#10 OR #11)NOT #9 21
#13 #8 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 111
#14 #13 NOT(#9 OR #12) 86

Cochrane Library

検索日:2018 年3 月21 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 ((Fluorodeoxyglucose:ti,ab,kw OR FDG:ti,ab,kw)AND(Positron Emission Tomography Computed Tomograph:ti,ab,kw OR Positron Emission Tomography CT:ti,ab,kw OR PET computed tomograph:ti,ab,kw OR PET CT:ti,ab,kw OR CT PET:ti,ab,kw OR PET scan:ti,ab,kw OR PET imaging:ti,ab,kw))OR FDG PET:ti,ab,kw 29,314
#03 Neoplasm Staging:ti,ab,kw OR Tumor Staging:ti,ab,kw OR Cancer Staging: ti,ab,kw OR TNM Staging:ti,ab,kw OR TNM Classification:ti,ab,kw OR timing: ti,ab,kw OR recurren:ti,ab,kw 62,874
#04 #1 and #2 and #3 3
#05 #4 CDSR 0
#06 #4 CCRCT 3

画像4(CQ)  GIST に対する薬物療法の治療効果判定にFDG-PET/CT の追加は有用か

PubMed

検索日:2018 年3 月21 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH] 1,932
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(diagnos[TW]OR detect[TW]OR screening[TW]) 4,948
#03 “Tomography, X‒Ray Computed”[MH]OR “Magnetic Resonance Imaging”[MH] 693,548
#04 “Computed Tomography”[TIAB]OR “Computed X Ray Tomography”[TIAB]OR “Computer Assisted Tomography”[TIAB]OR “Computerized Tomography”[TIAB]OR CT X Ray[TIAB]OR Tomodensitometry[TIAB]OR X‒Ray CAT Scan[TIAB]OR X‒Ray CT Scan[TIAB]OR Cine CT[TIAB]OR “Electron Beam Tomography”[TIAB]OR “X Ray Computerized Axial Tomography”[TIAB]OR Magnetic Resonance Imaging[TIAB]OR “NMR Imaging”[TIAB]OR “MR Tomography”[TIAB]OR “NMR Tomography”[TIAB]OR MRI[TIAB]OR Zeugmatography[TIAB]OR Chemical Shift Imaging[TIAB]OR “Proton Spin Tomography”[TIAB]OR “Magnetization Transfer Contrast Imaging”[TIAB]OR MRI Scan[TIAB]OR fMRI[TIAB]OR Functional MRI[TIAB]OR Spin Echo Imaging[TIAB] 521,916
#05 “Positron Emission Tomography Computed Tomography”[MH]AND ”Fluorodeoxyglucose F18”[MH] 1,524
#06 ((Fluorodeoxyglucose[TIAB]OR FDG[TIAB])AND(Positron Emission Tomography Computed Tomograph[TIAB]OR Positron Emission Tomography CT[TIAB]OR PET computed tomograph[TIAB]OR PET CT[TIAB]OR CT PET[TIAB]OR PET scan[TIAB]OR PET imaging[TIAB]))OR FDG PET[TIAB] 25,372
#07 “Treatment Outcome”[MH] 858,595
#08 Treatment Outcome[TIAB]OR therapeutic effect[TIAB]OR therapeutic response[TIAB]OR Treatment Assess[TIAB]OR response assessment[TIAB]OR treatment response[TIAB]OR Response Evaluation[TIAB]OR response criteria[TIAB] 133,942
#09 (#1 OR #2)AND(#3 OR #4 OR #5 OR #6)AND(#7 OR #8) 265
#10 #9 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 6
#11 #9 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 11
#12 #9 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 35
#13 (#11 OR #12)NOT #10 35
#14 #9 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 222
#15 #14 NOT(#10 OR #13) 183

Cochrane Library

検索日:2018 年3 月21 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 “Computed Tomography”:ti,ab,kw or “Computed X Ray Tomography”:ti,ab,kw or “Computer Assisted Tomography”: ti, ab, kw or “Computerized Tomography”:ti,ab,kw or “CT X Ray”:ti,ab,kw or Tomodensitometry:ti,ab,kw or “X‒Ray CAT Scan”:ti,ab,kw or “X‒Ray CT Scan”:ti,ab,kw or “Cine CT”:ti,ab,kw or “Electron Beam Tomography”:ti,ab,kw or “X Ray Computerized Axial Tomography”:ti,ab,kw or “Magnetic Resonance Imaging”:ti,ab,kw or “NMR Imaging”:ti,ab,kw or “MR Tomography”:ti,ab,kw or “NMR Tomography”:ti,ab,kw or MRI:ti,ab,kw or Zeugmatography:ti,ab,kw or “Chemical Shift Imaging”:ti,ab,kw or “Proton Spin Tomography”:ti,ab,kw or “Magnetization Transfer Contrast Imaging”:ti,ab,kw or “MRI Scan”:ti,ab,kw or fMRI:ti,ab,kw or “Functional MRI”:ti,ab,kw or “Spin Echo Imaging”:ti,ab,kw 29,314
#03 ((Fluorodeoxyglucose:ti,ab,kw OR FDG:ti,ab,kw)AND(Positron Emission Tomography Computed Tomograph:ti,ab,kw OR Positron Emission Tomography CT:ti,ab,kw OR PET computed tomograph:ti,ab,kw OR PET CT:ti,ab,kw OR CT PET:ti,ab,kw OR PET scan:ti,ab,kw OR PET imaging:ti,ab,kw))OR FDG PET:ti,ab,kw 1,863
#04 Treatment Outcome:ti,ab,kw OR therapeutic effect:ti,ab,kw OR therapeutic response:ti,ab,kw OR Treatment Assess:ti,ab,kw OR response assessment: ti,ab,kw OR treatment response:ti,ab,kw OR Response Evaluation:ti,ab,kw OR response criteria:ti,ab,kw 437,175
#05 #1 and(#2 or #3)and #4 30
#06 #5 CDSR 0
#07 #5 CCRCT 30

2 病理診断領域

病理1(BQ)  GIST の鑑別にはHE 染色での形態診断とKIT 免疫染色は有用か

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH] 3,847
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(diagnos[TIAB]OR detect[TIAB]OR screening[TIAB]OR patholog[TIAB]OR histopatholog[TIAB]OR clinicopatholog[TIAB]) 4,706
#03 “Eosine Yellowish‒(YS)”[MH]AND “Hematoxylin”[MH] 994
#04 HE stain[TIAB]OR hematoxylin eosin stain[TIAB] 6,999
#05 “Proto‒Oncogene Proteins c‒kit”[MH] 7,936
#06 KIT[TIAB] 48,056
#07 “Diagnosis, Differential”[MH] 424,317
#08 Differential Diagnos[TIAB] 119,559
#09 (#1 OR #2)AND(#3 OR #4 OR #5 OR #6)AND(#7 OR #8) 249
#10 #9 AND 2013:2018[DP] 47
#11 #10 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 1
#12 #10 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 1
#13 #10 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 1
#14 #10 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 24
#15 (#12 OR #13 OR #14)NOT #11 23
#16 #10 NOT(#11 OR #15) 23

※病理1(BQ)については他CQ と同様,Cochrane Library の検索を実施しているが,検索結果が0 編であったため,日本医学図書館協会から検索式が納品されなかった。

病理2(BQ)  GIST の鑑別診断にKIT 以外の免疫染色は有用か

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH] 3,847
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(diagnos[TIAB]OR detect[TIAB]OR screening[TIAB]OR patholog[TIAB]OR histopatholog[TIAB]OR clinicopatholog[TIAB]OR immunohistochemi[TIAB]) 5,055
#03 “ANO1 protein, human”[Supplementary Concept] 274
#04 DOG1[TIAB]OR “DOG 1”[TIAB] 589
#05 “SDHB protein, human”[Supplementary Concept] 312
#06 succinate dehydrogenase subunit B[TIAB]OR SDBH[TIAB] 124
#07 (#1 OR #2)AND(#3 OR #4 OR #5 OR #6) 231
#08 #7 AND 2013:2018[DP] 155
#09 #8 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 3
#10 #8 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials
as Topic”[MH]OR(random[TIAB]NOT medline[SB]))
1
#11 #8 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 2
#12 #8 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 73
#13 (#10 OR #11 OR #12)NOT #9 73
#14 #8 NOT(#9 OR #13) 79

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 DOG1:ti,ab,kw OR “DOG 1”:ti,ab,kw 2
#03 succinate dehydrogenase subunit B:ti,ab,kw OR SDBH:ti,ab,kw 7
#04 #1 and(#2 or #3) 2
#05 #4 CDSR 0
#06 #4 CCRCT 2

病理3(BQ)  免疫染色でKIT 陰性または弱陽性のGIST の診断に遺伝子解析は有用か

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH]OR “Gastrointestinal Stromal Tumors/genetics”[MH] 4,236
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(diagnos[TW]OR detect[TW]OR screening[TW]OR patholog[TW]OR histopatholog[TW]OR clinicopatholog[TW]OR immunohistochemi[TW]OR genetic[TW]) 7,359
#03 “Proto‒Oncogene Proteins c‒kit”[MH]AND(negative[TIAB]OR weak[TIAB]) 1,105
#04 KIT[TIAB]AND(negative[TIAB]OR weak[TIAB]) 6,646
#05 “Mutation”[MH] 693,576
#06 Mutation[TIAB] 557,886
#07 “Receptor, Platelet‒Derived Growth Factor alpha”[MH] 2,153
#08 “Platelet Derived Growth Factor alpha Receptor”[TIAB]OR PDGFRalpha[TIAB]OR PDGF R alpha[TIAB]OR CD140a Antigen[TIAB]OR PDGFR2[TIAB]OR PDGF alpha Receptor[TIAB]OR PDGFRA[TIAB] 3,251
#09 (#1 OR #2)AND(#3 OR #4)AND(#5 OR #6 OR #7 OR #8) 281
#10 #9 AND 2013:2018[DP] 81
#11 #10 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 1
#12 #10 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 0
#13 #10 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 4
#14 #10 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 34
#15 (#12 OR #13 OR #14)NOT #11 34
#16 #10 NOT(#11 OR #15) 46

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 KIT:ti,ab,kw AND(negative:ti,ab,kw OR weak:ti,ab,kw) 267
#03 Mutation:ti,ab,kw 8,092
#04 “Platelet Derived Growth Factor alpha Receptor”:ti,ab,kw OR PDGFRalpha: ti,ab,kw OR PDGF R alpha:ti,ab,kw OR CD140a Antigen:ti,ab,kw OR PDGFR2: ti,ab,kw OR PDGF alpha Receptor:ti,ab,kw OR PDGFRA:ti,ab,kw 112
#05 #1 and #2 and(#3 or #4) 2
#06 #5 CDSR 0
#07 #5 CCRCT 2

画像4(BQ)  GIST は臓器別に頻度や悪性度に違いはあるか

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/pathology”[MH]OR “Gastrointestinal Stromal Tumors/genetics”[MH] 3,159
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(patholog[TW]OR histopatholog[TW]OR clinicopatholog[TW]OR immunohistochemi[TW]OR genetic[TW]) 6,102
#03 “Mitotic Index”[MH]OR “Phenotype”[MH]OR “Prognosis”[MH] 1,662,098
#04 mitotic[TIAB]OR phenotype[TIAB]OR prognos[TIAB] 926,706
#05 Site[TIAB] 1,219,552
#06 (#1 OR #2)AND(#3 OR #4)AND #5 329
#07 #6 AND 2013:2018[DP] 121
#08 #7 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 2
#09 #7 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 1
#10 #7 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 7
#11 #7 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 91
#12 (#9 OR #10 OR #11)NOT #8 91
#13 #7 NOT(#8 OR #12) 28

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 mitotic:ti,ab,kw OR phenotype:ti,ab,kw OR prognos:ti,ab,kw 38,538
#03 Site:ti,ab,kw 44,537
#04 #1 and #2 and #3 7
#05 #4 CDSR 0
#06 #4 CCRCT 7

病理5(BQ)  GIST の悪性度評価に再発リスク分類は有用か

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 (“Gastrointestinal Stromal Tumors/pathology[”MH]OR “Gastrointestinal Stromal Tumors/diagnosis”[MH])AND “Gastrointestinal Stromal Tumors/surgery”[MH] 1,335
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(patholog[TIAB]OR histopatholog[TIAB]OR clinicopatholog[TIAB]OR immunohistochemi[TIAB]OR diagnos[TIAB]OR detect[TIAB]OR screening[TIAB])AND(surg[TIAB]OR operati[TIAB]OR resection[TIAB]) 2,308
#03 “Prognosis”[MH] 1,401,466
#04 prognos[TIAB] 507,638
#05 “Risk Assessment”[MH]OR “Risk Factors”[MH] 878,178
#06 Risk Assessment[TIAB]OR Risk Factor[TIAB]OR risk classification[TIAB]OR modified[TIAB] 956,047
#07 “Mitotic Index”[MH]OR “Rupture”[MH] 50,561
#08 mitotic[TIAB]OR size[TIAB]OR rupture[TIAB] 1,078,673
#09 (#1 OR #2)AND(#3 OR #4)AND(#5 OR #6 OR #7 OR #8) 672
#10 #9 AND 2013:2018[DP] 271
#11 #10 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 10
#12 #10 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 5
#13 #10 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 24
#14 #10 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 211
#15 (#12 OR #13 OR #14)NOT #11 206
#16 #10 NOT(#11 OR #15) 55

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Neoplasm”:ti,ab,kw OR “Gastrointestinal Stromal Tumor”:ti,ab,kw OR “Gastrointestinal Stromal Sarcoma”:ti,ab,kw OR GIST:ti,ab,kw 353
#02 prognos:ti,ab,kw 33,936
#03 Risk Assessment:ti,ab,kw OR Risk Factor:ti,ab,kw OR risk classification: ti,ab,kw OR modified:ti,ab,kw OR mitotic:ti,ab,kw OR size:ti,ab,kw OR rupture: ti,ab,kw 166,096
#04 #1 and #2 and #3 21
#05 #4 CDSR 0
#06 #4 CCRCT 21

病理6(BQ)  GIST の悪性度(再発リスク)評価に生検は有用か

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH] 3,847
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(patholog[TW]OR histopatholog[TW]OR clinicopatholog[TW]OR cytopatholog[TW]OR biops[TW]) 5,222
#03 “Endoscopic Ultrasound‒Guided Fine Needle Aspiration”[MH] 1,651
#04 Endoscopic Ultrasound‒Guided Fine Needle Aspiration[TIAB]OR EUS‒FNA[TIAB] 2,309
#05 (#1 OR #2)AND(#3 OR #4) 127
#06 #5 AND 2013:2018[DP] 58
#07 #6 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 1
#08 #6 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 5
#09 #6 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 4
#10 #6 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 39
#11 (#8 OR #9 OR #10)NOT #7 40
#12 #6 NOT(#7 OR #11) 17

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 patholog:ti,ab,kw OR histopatholog:ti,ab,kw OR clinicopatholog:ti,ab,kw OR cytopatholog:ti,ab,kw OR biops:ti,ab,kw 40,271
#03 Endoscopic Ultrasound‒Guided Fine Needle Aspiration:ti,ab,kw OR EUS‒FNA: ti,ab,kw 291
#04 #1 and #2 and #3 19
#05 #4 CDSR 0
#06 #4 CCRCT 19

病理7(BQ)  GIST においてKIT 免疫染色とc-kit 遺伝子変異とは関係があるか

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/genetics”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH] 3,160
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(patholog[TW]OR histopatholog[TW]OR clinicopatholog[TW]OR cytopatholog[TW]OR immunohistochemi[TW]OR genetic[TW]) 6,108
#03 “Proto‒Oncogene Proteins c‒kit”[MH] 7,938
#04 KIT[TIAB] 48,075
#05 “Immunohistochemistry”[MH] 571,511
#06 Immunohistochemi[TIAB]OR Immunostain[TIAB]OR stain[TIAB] 652,385
#07 “Mutation”[MH] 693,640
#08 Mutation[TIAB] 557,992
#09 “Genotype”[MH] 366,185
#10 genotyp[TIAB]OR wild[TIAB] 591,951
#11 (#1 OR #2)AND(#3 OR #4)AND(#5 OR #6)AND(#7 OR #8)AND(#9 OR #10) 140
#12 #11 AND 2013:2018[DP] 54
#13 #12 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 0
#14 #12 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 0
#15 #12 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 1
#16 #12 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 16
#17 #14 OR #15 OR #16 16
#18 #12 NOT #17 38

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 KIT:ti,ab,kw 1,987
#03 Immunohistochemi:ti,ab,kw OR Immunostain:ti,ab,kw OR stain:ti,ab,kw 10,429
#04 Mutation:ti,ab,kw 8,092
#05 genotyp:ti,ab,kw OR wild:ti,ab,kw 12,752
#06 #1 and #2 and #3 and #4 and #5 1
#07 #1 and #2 and #3 and #5 1
#08 #7 CDSR 0
#09 #7 CCRCT 1

病理8(BQ)  イマチニブ一次耐性GIST における遺伝子解析は有用か

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/diagnosis”[MH]OR “Gastrointestinal Stromal Tumors/genetics”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH] 4,237
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB])AND(diagnos[TW]OR patholog[TW]OR histopatholog[TW]OR clinicopatholog[TW]OR cytopatholog[TW]OR immunohistochemi[TW]OR genetic[TW]) 7,208
#03 “Imatinib Mesylate”[MH] 9,238
#04 Imatinib[TIAB] 11,861
#05 “Drug Resistance, Neoplasm”[MH] 40,611
#06 primary[TIAB]AND resistan[TIAB] 51,717
#07 (#1 OR #2)AND(#3 OR #4)AND(#5 OR #6) 390
#08 #7 AND 2013:2018[DP] 126
#09 #8 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 6
#10 #8 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 6
#11 #8 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 16
#12 #8 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 49
#13 (#10 OR #11 OR #12)NOT #9 45
#14 #8 NOT(#9 OR #13) 75

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 Imatinib:ti,ab,kw 1,009
#03 primary:ti,ab,kw AND resistan:ti,ab,kw 8,067
#04 #1 and #2 and #3 19
#05 #4 CDSR 0
#06 #4 CCRCT 19

病理9(BQ)  c-kit・PDGFRA 遺伝子以外の異常により発生するGIST はあるか

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/genetics”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH] 3,160
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(patholog[TW]OR histopatholog[TW]OR clinicopatholog[TW]OR cytopatholog[TW]OR immunohistochemi[TW]OR genetic[TW]) 6,164
#03 “Neurofibromatosis 1”[MH]OR “Genes, Neurofibromatosis 1”[MH] 9,441
#04 Neurofibromatosis[TIAB]OR NF1[TIAB]OR NF1[TIAB] 15,461
#05 “SDHB protein, human”[Supplementary Concept]OR “BRAF protein, human”[Supplementary Concept] 5,365
#06 SDHB[TIAB]OR SDH[TW]OR BRAF[TIAB]OR B RAF[TIAB] 17,650
#07 “Genotype”[MH] 366,185
#08 genotyp[TIAB] 273,539
#09 (#1 OR #2)AND(#3 OR #4 OR #5 OR #6)AND(#7 OR #8) 75
#10 #9 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 0
#11 #9 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 0
#12 #9 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 3
#13 #9 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 29
#14 #11 OR #12 OR #13 29
#15 #9 NOT #14 46

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 Neurofibromatosis:ti,ab,kw OR NF1:ti,ab,kw OR NF1:ti,ab,kw OR SDH:ti,ab,kw OR BRAF:ti,ab,kw OR B RAF:ti,ab,kw 3,368
#03 genotyp:ti,ab,kw 11,083
#04 #1 and #2 and #3 4
#05 #4 CDSR 0
#06 #4 CCRCT 4

病理10(BQ)  GIST が多発する病態はあるか

PubMed

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/genetics”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH] 3,160
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(patholog[TW]OR histopatholog[TW]OR clinicopatholog[TW]OR cytopatholog[TW]OR immunohistochemi[TW]OR genetic[TW]) 6,164
#03 “Neurofibromatosis 1”[MH]OR “Genes, Neurofibromatosis 1”[MH] 9,441
#04 Neurofibromatosis[TIAB]OR NF1[TIAB]OR NF1[TIAB] 15,461
#05 multiple[TIAB]OR familial[TIAB] 1,151,455
#06 SDH[TW] 6,081
#07 “Mutation”[MH] 693,640
#08 Germ Line[TIAB]OR Germline[TIAB] 35,985
#09 (#1 OR #2)AND(#3 OR #4 OR #5 OR #6)AND(#7 OR #8) 313
#10 #9 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 3
#11 #9 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 2
#12 #9 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 6
#13 #9 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB]OR Specificit[TIAB]OR Sensitivit[TIAB]OR accurac[TIAB])NOT medline[SB])) 142
#14 (#11 OR #12 OR #13)NOT #10 140
#15 #9 NOT(#10 OR #14) 170

Cochrane Library

検索日:2018 年3 月23 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 multiple:ti,ab,kw OR familial:ti,ab,kw OR Neurofibromatosis:ti,ab,kw OR NF1:ti,ab,kw OR NF1:ti,ab,kw OR SDH:ti,ab,kw 56,438
#03 Germ Line:ti,ab,kw OR Germline:ti,ab,kw OR mutation:ti,ab,kw 8,257
#04 #1 and #2 and #3 12
#05 #4 CDSR 0
#06 #4 CCRCT 12

3 外科治療領域

外科1(CQ)  2 cm 未満の胃GIST に対して,外科切除は推奨されるか

PubMed

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/surgery”[MH]OR “Gastrointestinal Stromal Tumors/pathology”[MH] 3,581
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB])AND(surgery[TIAB]OR surgical[TIAB]OR operative[TIAB]OR operation[TIAB]OR patholog[TIAB]) 3,619
#03 small[TIAB]AND size[TIAB] 130,834
#04 (#1 OR #2)AND #3 379
#05 #4 AND 2013:2018[DP] 153
#06 #5 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 6
#07 #5 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 3
#08 #5 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 7
#09 #5 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 84
#10 (#7 OR #8 OR #9)NOT #6 81
#11 #5 NOT(#6 OR #10) 66

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw OR patholog:ti,ab,kw 156,267
#03 small:ti,ab,kw AND size:ti,ab,kw 8,738
#04 #1 and #2 and #3 7
#05 #4 CDSR 1
#06 #4 CCRCT 6

外科2(CQ)  2 cm 以上,5 cm 未満の粘膜下腫瘍に対して,外科切除は推奨されるか

PubMed

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/surgery”[MH] 1,868
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB]OR SMT[TIAB]OR submucosal tumo[TIAB])AND(surgery[TIAB]OR surgical[TIAB]OR operative[TIAB]OR operation[TIAB]) 3,526
#03 tumour size[TIAB]OR tumor size[TIAB] 45,671
#04 (#1 OR #2)AND #3 582
#05 #4 AND 2013:2018[DP] 273
#06 #5 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 7
#07 #5 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 2
#08 #5 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 23
#09 (#7 OR #8)NOT #6 23
#10 #5 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 182
#11 #10 NOT(#6 OR #9) 159

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw OR SMT:ti,ab,kw OR submucosal tumo:ti,ab,kw 967
#02 surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw 148,943
#03 tumour size:ti,ab,kw OR tumor size:ti,ab,kw 5,112
#04 #1 and #2 and #3 84
#05 #4 CDSR 5
#06 #4 CCRCT 79

外科3(CQ)  5 cm 以上の粘膜下腫瘍に対して,腹腔鏡下手術は推奨されるか

PubMed

検索日(第2 回):2018 年4 月11 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/surgery”[MH] 1,869
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB]OR SMT[TIAB]OR submucosal tumo[TIAB])AND(surgery[TIAB]OR surgical[TIAB]OR operative[TIAB]OR operation[TIAB]) 3,529
#03 “Laparoscopy”[MH] 86,207
#04 Laparoscop[TIAB]OR Celioscop[TIAB]OR Peritoneoscop[TIAB] 11,689
#05 (#1 OR #2)AND(#3 OR #4) 770
#06 #5 AND 2003:2018[DP] 748
#07 #6 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR “Consensus Development Conference”[PT]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 27
#08 #6 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 11
#09 #6 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 30
#10 (#8 OR #9)NOT #7 27
#11 #6 AND(“Epidemiologic Research Design”[MH]OR “Clinical Study”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Comparative Study”[PT]OR “Evaluation Studies”[PT]OR “Multicenter Study”[PT]OR “Validation Studies”[PT]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 306
#12 #11 NOT(#7 OR #10) 268

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR GISTs:ti,ab,kw OR subepithelial tumo:ti,ab,kw OR SMT:ti,ab,kw OR submucosal tumo:ti,ab,kw 970
#02 surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw 148,943
#03 Laparoscop:ti,ab,kw OR Celioscop:ti,ab,kw OR Peritoneoscop:ti,ab,kw 13,396
#04 #1 and #2 and #3 24
#05 #4 CDSR 6
#06 #4 CCRCT 15

外科4(BQ)  外科切除が適応となるGIST に対して,臓器機能温存手術は推奨されるか

PubMed

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/surgery”[MH] 1,868
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(surgery[TIAB]OR surgical[TIAB]OR operative[TIAB]OR operation[TIAB]) 2,834
#03 “Margins of Excision”[MH] 663
#04 microscopically positive margin[TIAB]OR R1 resection[TIAB] 906
#05 preserv[TIAB]OR conserv[TIAB]OR sparing[TIAB] 658,531
#06 (#1 OR #2)AND(#3 OR #4 OR #5) 242
#07 #6 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH] OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 8
#08 #6 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 1
#09 #6 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 16
#10 #6 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB] OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 144
#11 (#8 OR #9 OR #10)NOT #7 143
#12 #6 NOT(#7 OR #11) 91

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 surgery:ti,ab,kw OR surgical:ti,ab,kw OR operat:ti,ab,kw 166,229
#03 preserv:ti,ab,kw OR conserv:ti,ab,kw OR sparing:ti,ab,kw OR microscopically positive margin:ti,ab,kw OR R1 resection:ti,ab,kw 24,878
#04 #1 and #2 and #3 9
#05 #4 CDSR 3
#06 #4 CCRCT 6

外科5(CQ)  大きなGIST や,不完全切除の可能性が高いと判断されるGIST に対して,イマチニブによる術前補助療法は有用か

PubMed

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/drug therapy”[MH] 1,576
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(drug therap[TW]OR chemotherap[TW]OR pharmacotherap[TW]) 2,479
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,735
#04 “Neoadjuvant Therapy”[MH]OR Neoadjuvant[TW] 30,957
#05 (#1 OR #2)AND #3 AND #4 210
#06 #5 AND 2013:2018[DP] 64
#07 #6 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 3
#08 #6 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 1
#09 #6 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 7
#10 #6 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 43
#11 (#8 OR #9 OR #10)NOT #7 43
#12 #6 NOT(#7 OR #11) 18

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 drug therap:ti,ab,kw OR chemotherap:ti,ab,kw OR pharmacotherap:ti,ab,kw 289,404
#03 Imatinib:ti,ab,kw 1,009
#04 Neoadjuvant:ti,ab,kw 4,328
#05 #1 and #2 and #3 and #4 5
#06 #5 CDSR 0
#07 #5 CCRCT 5

外科6(CQ)  術前もしくは術中に腫瘍破裂が確認されたGIST に対して,イマチニブによる術後補助療法は有用か

PubMed

検索日(第2 回):2018 年4 月10 日(火)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/drug therapy”[MH]OR “Gastrointestinal Stromal Tumors/surgery”[MH] 3,005
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(drug therap[TW]OR chemotherap[TW]OR pharmacotherap[TW]OR surgery[TW]OR surgical[TW]OR operative[TW]OR operation[TW]OR postoperative[TW]) 5,223
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,752
#04 “Chemotherapy, Adjuvant”[MH]OR adjuvant[TW] 185,079
#05 rupture[TW]OR microscopically positive margin[TIAB] 118,393
#06 (#1 OR #2)AND #3 AND #4 AND #5 45
#07 (#1 OR #2)AND #5 152
#08 #7 NOT #6 107

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 drug therap:ti,ab,kw OR chemotherap:ti,ab,kw OR pharmacotherap:ti,ab,kw OR surgery:ti,ab,kw OR surgical:ti,ab,kw OR operative:ti,ab,kw OR operation:ti,ab,kw OR postoperative:ti,ab,kw 420,717
#03 Imatinib:ti,ab,kw 1,009
#04 adjuvant:ti,ab,kw 23,282
#05 #1 and #2 and #3 and #4 43
#06 #5 CDSR 0
#07 #5 CCRCT 36

外科7(BQ)  完全切除後のGIST に対して,定期フォローは有用か

PubMed

検索日(第2 回):2018 年4 月10 日(火)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/surgery”[MH] 1,869
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(surgical[TW]OR surgery[TW]OR operative[TW]OR operation[TW]) 3,656
#03 follow up[TW]OR surveillance[TW]OR recurrence interval[TIAB]OR recurrence pattern[TIAB] 1,331,162
#04 (#1 OR #2)AND #3 1,141
#05 #4 AND 2013:2018[DP] 464
#06 #5 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 21
#07 #5 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 9
#08 #5 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 40
#09 (#7 OR #8)NOT #6 38
#10 #5 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 332
#11 #10 NOT(#6 OR #9) 283

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 surgical:ti,ab,kw OR surgery:ti,ab,kw OR operative:ti,ab,kw OR operation:ti,ab,kw 154,495
#03 follow up:ti,ab,kw OR surveillance:ti,ab,kw OR prognos:ti,ab,kw 195,432
#04 after:ti,ab,kw OR postoperat:ti,ab,kw OR post operat:ti,ab,kw 456,428
#05 #1 and #2 and #3 and #4 43
#06 #5 CDSR 12
#07 #5 CCRCT 30

外科8(CQ)  転移性GIST に対して,初回治療としての外科切除は有用か

PubMed

検索日(第2 回):2018 年4 月10 日(火)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/surgery”[MH] 1,869
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(surgical[TW]OR surgery[TW]OR operative[TW]OR operation[TW]OR Metastasectom[TW]) 3,658
#03 “Neoplasm Metastasis”[MH]OR “Neoplasm Recurrence, Local”[MH]OR “Metastasectomy”[MH]OR “secondary”[SH] 372,276
#04 metastas[TW]OR metastat[TW]OR secondary[TW]OR recurren[TW] 1,621,808
#05 (#1 OR #2)AND(#3 OR #4) 2,029
#06 #5 AND 2013:2018[DP] 820
#07 #6 AND(JAPANESE[LA]OR ENGLISH[LA]) 751
#08 #7 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR “Consensus Development Conference”[PT]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 46
#09 #7 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 17
#10 #7 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 58
#11 (#9 OR #10)NOT #8 52
#12 #7 AND(“Epidemiologic Research Design”[MH]OR “Clinical Study”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Comparative Study”[PT]OR “Evaluation Studies”[PT]OR “Multicenter Study”[PT]OR “Validation Studies”[PT]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 316
#13 #12 NOT(#8 OR #11) 249

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 surgical:ti,ab,kw OR surgery:ti,ab,kw OR operative:ti,ab,kw OR operation:ti,ab,kw OR Metastasectom:ti,ab,kw 154,518
#03 metastas:ti,ab,kw OR metastat:ti,ab,kw OR secondary:ti,ab,kw OR recurren: ti,ab,kw 139,134
#04 #1 and #2 and #3 68
#05 #4 CDSR 11
#06 #4 CCRCT 56

外科9(CQ)  イマチニブ奏効中の転移・再発GIST に対して,外科切除は有用か

PubMed

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/surgery”[MH] 1,868
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(surgical[TW]OR surgery[TW]OR operative[TW]OR operation[TW]) 3,654
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,737
#04 “Dose‒Response Relationship, Drug”[MH]OR respond[TIAB]OR respons[TIAB]OR sensitive[TIAB]OR metasta[TIAB] 4,172,798
#05 (#1 OR #2)AND #3 AND #4 745
#06 #5 AND 2013:2018[DP] 256
#07 #6 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 15
#08 #6 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 10
#09 #6 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 27
#10 (#8 OR #9)NOT #7 23
#11 #6 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 148
#12 #11 NOT(#7 OR #10) 123

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 surgical:ti,ab,kw OR surgery:ti,ab,kw OR operative:ti,ab,kw OR operation:ti,ab,kw 154,495
#03 Imatinib:ti,ab,kw 1,009
#04 respond:ti,ab,kw OR respons:ti,ab,kw OR sensitive:ti,ab,kw OR metasta: ti,ab,kw 235,938
#05 #1 and #2 and #3 and #4 22
#06 #5 CDSR 0
#07 #5 CCRCT 22

外科10(CQ)  薬剤耐性の転移・再発GIST に対して,外科切除は有用か

PubMed

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/surgery”[MH] 1,868
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB])AND(surgical[TW]OR surgery[TW]OR operative[TW]OR operation[TW]) 3,654
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,737
#04 “Drug Resistance”[MH]OR “Disease Progression”[MH]OR resistan[TIAB]OR progressi[TIAB] 1,678,078
#05 (#1 OR #2)AND #3 AND #4 379
#06 (#1 OR #2)AND #4 512
#07 #6 AND 2013:2018[DP] 209
#08 #7 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 9
#09 #7 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 7
#10 #7 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 22
#11 #7 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 122
#12 (#9 OR #10 OR #11)NOT #8 119
#13 #7 NOT(#8 OR #12) 81

Cochrane Library

検索日:2018 年3 月28 日(水)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 surgical:ti,ab,kw OR surgery:ti,ab,kw OR operative:ti,ab,kw OR operation:ti,ab,kw 154,495
#03 Imatinib:ti,ab,kw 1,009
#04 resistan:ti,ab,kw OR progressi:ti,ab,kw 92,270
#05 #1 and #2 and #3 and #4 15
#06 #5 CDSR 0
#07 #5 CCRCT 15

4 内科治療領域

内科1(CQ)  標準用量開始が可能な転移・再発GIST に対して,イマチニブの標準用量開始と比べて低用量開始は有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors”[MH] 5,462
#02 Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB] 9,309
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,739
#04 low dos[TW]OR lower dos[TW] 135,294
#05 (#1 OR #2)AND #3 AND #4 30
#06 #5 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 1
#07 #5 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 3
#08 #5 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB] 6
#09 #5 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 25
#10 (#7 OR #8 OR #9)NOT #6 25
#11 #5 NOT(#6 OR #10) 4

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 Imatinib:ti,ab,kw 1,034
#03 low dos:ti,ab,kw AND low imatinib:ti,ab,kw 85
#04 #1 and #2 and #3 5
#05 #4 CDSR 0
#06 #4 CCRCT 5

内科2(BQ)  転移・再発GIST に対して,チロシンキナーゼ阻害薬が有効性を示した場合,治療中断は有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/drug therapy”[MH] 1,577
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB])AND(drug therap[TW]OR chemotherap[TW]) 2,479
#03 “Protein Kinase Inhibitors”[MH]OR “Protein Kinase Inhibitors”[PA]OR Tyrosine Kinase Inhibitor[TIAB]OR TKI[TIAB] 100,936
#04 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,739
#05 “sunitinib”[Supplementary Concept]OR sunitinib[TW] 5,160
#06 “regorafenib”[Supplementary Concept]OR regorafenib[TW] 634
#07 continu[TIAB]OR interrupt[TIAB]OR discontinu[TIAB] 1,040,079
#08 (#1 OR #2)AND(#3 OR #4 OR #5 OR #6)AND #7 288
#09 #8 AND 2013:2018[DP] 102
#10 #9 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 6
#11 #9 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 11
#12 #9 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 25
#13 #9 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 69
#14 (#7 OR #8 OR #9)NOT #6 65
#15 #9 NOT(#6 OR #10) 31

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 Tyrosine Kinase Inhibitor:ti,ab,kw OR TKI:ti,ab,kw OR Imatinib:ti,ab,kw OR sunitinib:ti,ab,kw OR regorafenib:ti,ab,kw 3,439
#03 continu:ti,ab,kw OR interrupt:ti,ab,kw OR discontinu:ti,ab,kw 101,145
#04 #1 and #2 and #3 50
#05 #4 CDSR 0
#06 #4 CCRCT 50

内科3(CQ)  転移・再発GIST に対して,イマチニブの血中濃度測定は有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors”[MH] 5,462
#02 Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB] 9,309
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,739
#04 blood level[TIAB]OR trough level[TIAB]OR plasma level[TIAB]OR blood concentration[TIAB]OR trough concentration[TIAB]OR plasma concentration[TIAB] 170,294
#05 (#1 OR #2)AND #3 AND #4 65
#06 #5 AND 2013:2018[DP] 22
#07 #6 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 0
#08 #6 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 1
#09 #6 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 3
#10 #6 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 10
#11 #8 OR #9 OR #10 10
#12 #6 NOT #11 12

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 Imatinib:ti,ab,kw 1,034
#03 blood level:ti,ab,kw OR trough level:ti,ab,kw OR plasma level:ti,ab,kw OR blood concentration:ti,ab,kw OR trough concentration:ti,ab,kw OR plasma concentration: ti,ab,kw 157,770
#04 #1 and #2 and #3 23
#05 #4 CDSR 0
#06 #4 CCRCT 23

内科4(CQ)  イマチニブ400 mg/日投与中に増悪した転移・再発GIST に対して,投与量増加は有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors”[MH] 5,462
#02 Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB] 9,309
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,739
#04 dose escalation[TW]OR high dos[TW]OR higher dos[TW] 169,595
#05 (#1 OR #2)AND #3 AND #4 76
#06 #5 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 12
#07 #5 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 9
#08 #5 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 28
#09 #5 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 50
#10 (#7 OR #8 OR #9)NOT #6 41
#11 #5 NOT(#6 OR #10) 23

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw 478
#02 Imatinib:ti,ab,kw 1,034
#03 dose escalation:ti,ab,kw OR high dos:ti,ab,kw OR higher dos:ti,ab,kw 91,747
#04 #1 and #2 and #3 32
#05 #4 CDSR 0
#06 #4 CCRCT 29

内科5-1(BQ)  再発高リスクまたは腫瘍破裂GIST に対して,完全切除後3 年間のイマチニブによる術後補助療法は有用か
内科5-2(CQ)  再発高リスクまたは腫瘍破裂GIST に対して,完全切除後3 年間を超えるイマチニブによる術後補助療法は有用か

PubMed

検索日:2018 年4 月6 日(金)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/therapy”[MH] 3,438
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB])AND(therap[TIAB]OR chemotherap[TIAB]OR treatment[TIAB]OR pharmacotherap[TIAB]) 4,695
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,747
#04 “Chemotherapy, Adjuvant”[MH]OR adjuvant[TIAB]OR(after[TIAB]AND(operation[TIAB]OR operative[TIAB]OR operable[TIAB]OR surgery[TIAB]OR surgical[TIAB]OR resect[TIAB]))OR postoperative[TIAB]OR post operative[TIAB] 1,160,109
#05 “Rupture”[MH]OR Rupture[TIAB] 131,603
#06 “Risk”[MH]OR High Risk[TIAB] 1,207,870
#07 (#1 OR #2)AND #3 AND #4 AND(#5 OR #6) 333
#08 #7 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 21
#09 #7 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 25
#10 #7 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 47
#11 #7 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 207
#12 (#9 OR #10 OR #11)NOT #8 196
#13 #7 NOT(#8 OR #12) 116
#14 (#1 OR #2)AND #3 AND #4 1,030
#15 #14 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 50
#16 #15 NOT #7 29
#17 #14 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 49
#18 #17 NOT(#7 OR #16) 22
#19 #14 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 125
#20 #19 NOT(#7 OR #16 OR #18) 51

Cochrane Library

検索日:2018 年4 月6 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 adjuvant:ti,ab,kw OR(after:ti,ab,kw AND(operation:ti,ab,kw OR operative: ti,ab,kw OR operable:ti,ab,kw OR surgery:ti,ab,kw OR surgical:ti,ab,kw OR resect:ti,ab,kw))OR postoperative:ti,ab,kw OR post operative:ti,ab,kw 147,299
#03 imatinib:ti,ab,kw 1,034
#04 Rupture:ti,ab,kw OR High Risk:ti,ab,kw 65,029
#05 #1 and #2 and #3 not #4 35
#06 #5 CDSR 0
#07 #5 CCRCT 26

内科6(BQ)  イマチニブ不耐・不応の転移・再発GIST に対して,スニチニブは有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/drug therapy”[MH] 1,577
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB])AND(drug therap[TIAB]OR chemotherap[TIAB]OR chemotherap[TIAB]) 626
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,740
#04 “sunitinib”[Supplementary Concept]OR sunitinib[TW] 5,162
#05 (#1 OR #2)AND #3 AND #4 AND failure[TIAB] 68
#06 (#1 OR #2)AND #3 AND #4 339
#07 #6 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 25
#08 #6 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 26
#09 #6 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 87
#10 (#8 OR #9)NOT #7 79
#11 #6 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 179
#12 #11 NOT(#7 OR #10) 92

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 Imatinib:ti,ab,kw 1,034
#03 sunitinib:ti,ab,kw 696
#04 #1 and #2 and #3 63
#05 #4 CDSR 0
#06 failure:ti,ab,kw 64,560
#07 #1 and #2 and #3 and #6 36
#08 #7 CCRCT 35

内科7(BQ)  スニチニブ不耐・不応の転移・再発GIST に対して,レゴラフェニブは有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/drug therapy”[MH] 1,577
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB])AND(drug therap[TIAB]OR chemotherap[TIAB]OR chemotherap[TIAB]) 626
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,740
#04 “sunitinib”[Supplementary Concept]OR sunitinib[TW] 5,162
#05 “regorafenib”[Supplementary Concept]OR regorafenib[TW] 634
#06 (#1 OR #2)AND(#3 OR #4)AND #5 AND failure[TIAB] 16
#07 (#1 OR #2)AND #5 64
#08 #7 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 10
#09 #7 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 8
#10 #7 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 23
#11 #7 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 36
#12 (#9 OR #10 OR #11)NOT #8 30
#13 #7 NOT(#8 OR #12) 24

Cochrane Library

検索日:2018 年3 月30 日(金)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 regorafenib:ti,ab,kw 238
#03 #1 and #2 50
#04 #3 CDSR 0
#05 #3 CCRCT 50

内科8(CQ)  レゴラフェニブ不耐・不応の転移・再発GIST に対して,イマチニブまたはスニチニブの再投与は有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors”[MH] 5,462
#02 Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB] 9,450
#03 “Imatinib Mesylate”[MH]OR Imatinib[TW] 13,740
#04 “sunitinib”[Supplementary Concept]OR sunitinib[TW] 5,162
#05 (#1 OR #2)AND(#3 OR #4) 3,147
#06 #5 AND(rechallenge[TIAB]OR regorafenib[TW]) 108
#07 #6 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 15
#08 #6 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 15
#09 #6 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 26
#10 #6 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 52
#11 (#8 OR #9 OR #10)NOT #7 43
#12 #6 NOT(#7 OR #11) 50

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 Imatinib:ti,ab,kw 1,034
#03 sunitinib:ti,ab,kw 696
#04 rechallenge:ti,ab,kw OR regorafenib:ti,ab,kw 502
#05 #1 and(#2 or #3)and #4 40
#06 #5 CDSR 0
#07 #5 CCRCT 40

内科9(CQ)  転移・再発GIST に対して,放射線治療は有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/radiotherapy”[MH] 9
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB])AND(radiotherap[TIAB]OR radiation therap[TIAB]OR irradiation[TIAB]) 180
#03 “Neoplasm Metastasis”[MH]OR “Neoplasms/secondary”[MH]OR metasta[TIAB]OR secondar[TIAB] 1,092,258
#04 (#1 OR #2)AND #3 99
#05 #4 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 7
#06 #4 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 3
#07 ##4 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 18
#08 #4 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 59
#09 (#6 OR #7 OR #8)NOT #5 59
#10 #4 NOT(#5 OR #9) 33

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 radiotherap:ti,ab,kw OR radiation therap:ti,ab,kw OR irradiation:ti,ab,kw 28,374
#03 metasta:ti,ab,kw OR secondar:ti,ab,kw 105,998
#04 #1 and #2 and #3 15
#05 #4 CDSR 9
#06 #4 CCRCT 6

内科10(CQ)  GIST の肝転移に対して,外科切除以外の局所療法は有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors/therapy”[MH] 3,438
#02 (Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB])AND(therap[TIAB]OR treatment[TIAB]OR rfa[TIAB]OR radiofrequency ablation[TIAB]) 4,580
#03 “Liver Neoplasms/secondary”[MH]OR(“Liver Neoplasms”[MH]AND “Neoplasm Metastasis”[MH])OR((liver neoplasm[TIAB]OR liver cancer[TIAB]OR heptaic neoplasm[TIAB]OR hepatic cancer[TIAB]OR Hepatocellular Cancer[TIAB])AND(metasta[TIAB]OR secondar[TIAB])) 36,890
#04 (#1 OR #2)AND #3 277
#05 #4 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 3
#06 #4 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 8
#07 #4 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 22
#08 #4 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 224
#09 (#6 OR #7 OR #8)NOT #5 224
#10 #4 NOT(#5 OR #9) 50

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 therap:ti,ab,kw OR treatment:ti,ab,kw OR rfa:ti,ab,kw OR radiofrequency ablation:ti,ab,kw 662,528
#03 (liver neoplasm:ti,ab,kw OR liver cancer:ti,ab,kw OR heptaic neoplasm: ti,ab,kw OR hepatic cancer:ti,ab,kw OR Hepatocellular Cancer:ti,ab,kw)AND(metasta:ti,ab,kw OR secondar:ti,ab,kw) 3,820
#04 #1 and #2 and #3 30
#05 #4 CDSR 7
#06 #4 CCRCT 23

内科11(CQ)  スニチニブおよびレゴラフェニブの標準用法用量の不耐GIST に対して,スニチニブおよびレゴラフェニブの投与スケジュールの変更は推奨されるか

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors”[MH] 9,450
#02 Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB] 709
#03 “sunitinib”[Supplementary Concept]OR sunitinib[TW] 5,162
#04 “regorafenib”[Supplementary Concept]OR regorafenib[TW] 634
#05 (#1 OR #2)AND(#3 OR #4)AND schedule[TIAB] 46
#06 #5 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 3
#07 #5 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB]) 5
#08 #5 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 18
#09 #5 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 23
#10 (#7 OR #8 OR #9)NOT #6 22
#11 #5 NOT(#6 OR #10) 21

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 sunitinib:ti,ab,kw 696
#03 regorafenib:ti,ab,kw 238
#04 schedule:ti,ab,kw 52,481
#05 #1 and(#2 or #3)and #4 15
#06 #5 CDSR 0
#07 #5 CCRCT 15

内科12(CQ)  GIST 治療におけるチロシンキナーゼ阻害薬の選択に遺伝子解析は有用か

PubMed

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 “Gastrointestinal Stromal Tumors”[MH] 5,462
#02 Gastrointestinal Stromal Neoplasm[TIAB]OR Gastrointestinal Stromal Tumo[TIAB]OR Gastrointestinal Stromal Sarcoma[TIAB]OR GIST[TIAB]OR GISTs[TIAB]OR subepithelial tumo[TIAB] 9,450
#03 “Protein Kinase Inhibitors”[MH]OR “Protein Kinase Inhibitors”[PA]OR Tyrosine Kinase Inhibitor[TIAB]OR TKI[TIAB] 100,939
#04 “Sequence Analysis”[MH]OR “genetics”[SH]OR gene analy[TIAB]OR molecular analy[TIAB] 3,105,422
#05 (#1 OR #2)AND #3 AND #4 778
#06 #5 AND(“Cochrane Database Syst Rev”[TA]OR “Meta‒Analysis”[PT]OR systematic[SB]OR “Guideline”[PT]OR “Guidelines as Topic”[MH]OR “Consensus”[MH]OR “Consensus Development Conferences as Topic”[MH]OR((meta‒analysis[TI]OR guideline[TI]OR “systematic review”[TI]OR consensus[TI])NOT Medline[SB])) 36
#07 #5 AND(“Randomized Controlled Trial”[PT]OR “Randomized Controlled Trials as Topic”[MH]OR(random[TIAB]NOT medline[SB])) 31
#08 #5 AND(“Clinical Study”[PT]OR “Clinical Studies as Topic”[MH]OR((clinical trial[TIAB]OR clinical stud[TIAB]OR case control[TIAB]OR case comparison[TIAB]OR observational stud[TIAB])NOT medline[SB])) 100
#09 (#7 OR #8)NOT #6 95
#10 #5 AND(“Epidemiologic Research Design”[MH]OR “Study Characteristics”[PT]OR “Epidemiologic Study Characteristics”[MH]OR “Diagnosis, Differential”[MH]OR “Diagnostic Errors”[MH]OR((cohort[TIAB]OR comparative stud[TIAB]OR retrospective stud[TIAB]OR prospective stud[TIAB]OR longitudinal[TIAB]OR control group[TIAB])NOT medline[SB])) 312
#11 #10 NOT(#6 OR #9) 196

Cochrane Library

検索日:2018 年4 月1 日(日)

Search No Search Strategy Result
#01 Gastrointestinal Stromal Neoplasm:ti,ab,kw OR Gastrointestinal Stromal Tumo: ti,ab,kw OR Gastrointestinal Stromal Sarcoma:ti,ab,kw OR GIST:ti,ab,kw OR subepithelial tumo:ti,ab,kw 495
#02 Tyrosine Kinase Inhibitor:ti,ab,kw OR TKI:ti,ab,kw OR Imatinib:ti,ab,kw OR sunitinib:ti,ab,kw OR regorafenib:ti,ab,kw 3,439
#03 Sequence Analy:ti,ab,kw OR gene analy:ti,ab,kw OR molecular analy:ti,ab,kw 30,430
#04 #1 and #2 and #3 42
#05 #4 CDSR 1
#06 #4 CCRCT 40

内科13(CQ)  レゴラフェニブ不耐・不応の転移・再発GIST に対して,ピミテスピブは有用か

PubMed

2022 年9 月2 日(金)

Search No Search Strategy Result
#01 (“TAS-116″[All Fields] OR “TAS 116″[All Fields] OR “TAS116″[All Fields] OR “Pimitespib”[All Fields]) OR “TAS-116” [Supplementary Concept] 20
#02 “Gastrointestinal Stromal Tumors”[MeSH Terms] 7,375
#03 “gist*”[All Fields] OR “Gastrointestinal Stromal Tumor”[All Fields] OR “Gastrointestinal Stromal Tumors”[All Fields] 27,566
#04 #1 AND (#2 OR #3) 6
#05 English[Language] OR Japanese[Language] 30,199,905
#06 (“1900/1/1″[Date – Publication] : “2022/8/31″[Date – Publication]) 34,441,531
#07 #1 AND (#5 AND #6) 20

Cochrane Library

検索日:2022 年9 月2 日(金)

Search No Search Strategy Result
#01 “TAS-116” in All Text OR “TAS116” in All Text OR “TAS 116” in All Text OR Pimitespib in All Text – with Cochrane Library publication date Between Jan 1900 and Aug 2022, in Cochrane Reviews, Trials (Word variations have been searched) 7

各Question の投票結果内訳



外部評価

本ガイドラインは草案段階で,GIST 診療ガイドライン評価ワーキンググループによる外部評価(以下,ワーキンググループ評価),日本癌治療学会会員を対象としたパブリックコメント(以下,パブリックコメント),がん診療ガイドライン評価委員会によるAGREEⅡ評価(以下,AGREEⅡ評価)を受けた。

また,AGREEⅡ評価においては,施設間格差や医療経済的観点などに関する多くの示唆に富むコメントをいただき,今後のガイドライン改訂に活かすことが確認された。以下に,外部評価に対する具体的な対応を示す。誤字・脱字等の指摘には適宜対応した。

1 外部評価対応

(1)本ガイドラインの概要
  • AGREEⅡ評価にて診療ガイドラインの最終目的に関するコメントを受け,本ガイドラインの目的に,適切な医療の実践を通した患者の予後の改善であることを明確に記載した。
(2)アルゴリズム
  • アルゴリズム1 について,パブリックコメントにて,食道,胃,十二指腸,空腸,回腸,大腸で消化管の粘膜下腫瘍の組織型の頻度が異なっている等の理由で,部位によるアルゴリズムが必要ではないかとの指摘を受けたが,それぞれの部位における粘膜下腫瘍の取り扱いに関するデータが少ないことから,部位別のアルゴリズムの作成は困難との結論に達した。
  • アルゴリズム4 について,パブリックコメントにて,2 cm 未満の胃粘膜下腫瘍の取り扱いで悪性所見(潰瘍形成,辺縁不正,増大)が無い場合の経過観察の方法が明示されていない等の指摘をいただき,経過観察の表記部分に「EUS を含む内視鏡で実施」との注釈をつけることとした。
(3)画像診断領域
  • ワーキンググループ評価において,画像4(CQ)の,GIST の薬物療法における効果判定に際し,特に腹膜播種のリスクが高い症例ではFDG‒PET/CT を追加することが望ましいとの記載に対してエビデンスを示すようにとのコメントをいただき,4 つの文献を追加してわかりやすくすることとした。
(4)病理診断領域
  • ワーキンググループ評価で,病理9(BQ)のイマチニブの効果が期待できないような遺伝子異常が判明している場合にはイマチニブによる術後補助療法は安易に行うべきではないとの記載に関して,術前補助療法にも同様のことが言えるのではないかとのコメントをいただき,「術前・術後補助療法」という記載に変更した。
(5)外科治療領域
  • 外科7(BQ)に関するパブリックコメントとして,完全切除後の晩期再発を起こすGIST の存在に関して,その臨床的特徴や術後の観察期間についての記載が必要なのではないかとの意見をいただいたが,そのようなGIST を特定できるデータがないことから,次回以降の検討課題とすることとなった。
  • ワーキンググループ評価にて,外科総論および外科5(CQ)の推奨文に記載されている術前補助療法の適応症例に関し,10 cm 以上のGIST であれば胃だけでなく小腸でも適応されるのか,とのコメントをいただき,胃以外での術前補助療法の有効性のエビデンスが乏しいことから,解説文中に「ただし,胃以外のGIST に関してはエビデンスが乏しく,胃GIST のエビデンスを適応できるかどうかは不明である。」との記載を加えた。
(6)内科治療領域
  • 内科5-2(CQ)に対するパブリックコメントおよびワーキンググループ評価として,再発高リスクまたは腫瘍破裂GIST に対するlife long でのイマチニブ投与の方向性を記載すべきではないかとの指摘があったが,それによる有効性に関してのエビデンスの乏しさから,積極的な記載はしないこととした。
  • 内科総論および内科6(BQ)に対するワーキンググループ評価として,次世代シークエンシング(NGS)による遺伝子診断の適応等に関する記載についてのコメントをいただき,標準治療に不耐・不応あるいはc‒kit 遺伝子変異やPDGFRA 遺伝子変異を有しない場合には分析学的妥当性が確立されたNGS 検査等により,包括的なゲノムプロファイルを取得することが選択肢となることを追加記載することとなった。
  • 内科12(CQ)の推奨文に関するワーキンググループ評価として,より明確でわかり易い表現にすべきではないかとのコメントをいただいたが,議論の上,現状の記載は推奨文の書式に則っているものと判断され,変更はしないこととなった。
(7)ガイドライン全般
  • パブリックコメントとして,「術前補助療法」および「術後補助療法」の用語に関して,「術前療法」・「術後療法」とするのが妥当ではないかとの指摘があったが,他のガイドラインにおける状況等を鑑み,現状ではそのように変更すべきとまでは言えないとの結論となった。
  • AGREEⅡ評価において,各個人のCOI の公表に関する提言があり,WEB 版に掲載する方向となった。
  • パブリックコメントとして,CQ・BQ の「~は有用か」や「~は推奨されるか」の表現はどちらかに統一する方がよいのではないかとのコメントをいただいたが,既にその点に関しては議論を尽くしたうえでの文言となっていることから,変更はしない方針となった。

2 がん診療ガイドライン評価委員会によるAGREEⅡ評価結果

  項目 評価 コメント
DOMAIN 1. SCOPE AND PURPOSE
1 The overall objective(s)of the guideline is(are)specifically described. 6 項目立てて記載されていて,大変結構です。しかし診療ガイドラインの最終目的は,患者アウトカムの改善ではないかと存じます。診療方針を示した先にある,患者の予後を改善することにまで言及されると,さらに良いかと思います。
2 The health question(s)covered by the guideline is(are)specifically described. 6 CQ とBQ を使い分け,工夫されているのは,大変結構と思います。
一方でBQ の位置づけについては,今一度,ご検討をお願いしたいと存じます。BQ は,ほとんどの臨床家が実施している常識,基本的で不変的,これ以上エビデンスが出ない,といった内容が該当すると存じます。BQ にされた場合,エビデンスの強さは諸々あると思いますが,常識と位置づけられている内容ならば,推奨の強さは「1(強い)」と判断されるべきではないでしょうか。推奨の強さが「2(弱い)」と判断されるのであれば,BQ ではなくCQ とするべき内容ではないかと存じます。
CQ については,さらにPICO 形式を意識して書いていただければと存じます。
3 The population(patients, public, etc.)to whom the guideline is meant to apply is specifically described. 7 良く記載されていて結構と思います。
DOMAIN 2. STAKEHOLDER INVOLVEMENT
4 The guideline development group includes individuals from all relevant professional groups. 7 作成委員には,幅広い分野の専門家が揃っていて,結構と存じます。緩和ケアの専門家にもメンバーに入っていただくと,より良いと思います。
5 The views and preferences of the target population(patients, public, etc.)have been sought. 5 前版と比べ,患者の視点や意向についての記載が増えているのは,結構と存じます。こうした記載を増やしていただけると,さらに良いでしょう。
6 The target users of the guideline are clearly defined. 6  
DOMAIN 3. RIGOUR OF DEVELOPMENT
7 Systematic methods were used to search for evidence. 7  
8 The criteria for selecting the evidence are clearly described. 6 エビデンスの選択の過程について,さらに詳細な記載をお願いします。
9 The strengths and limitations of the body of evidence are clearly described. 5 エビデンス総体の評価を意識した記載がみられることは,結構と存じます。バイアスリスクや非直接性については評価されていますが,それ以外のlimitation についての記載も充実させると,さらに良いと思われます。
10 The methods for formulating the recommendations are clearly described. 7  
11 The health benefits, side effects, and risks have been considered in formulating the recommendations. 6 前版と比較して,記載は増えています。CQ ごとに,リスクや副作用などへの言及を増やされると,さらに良いと思います。
12 There is an explicit link between the recommendations and the supporting evidence. 6 前版と比較して,かなり改善されています。一方で,エビデンス総体の評価と推奨の関係が,不明瞭となっているCQ もみられます。
13 The guideline has been externally reviewed by experts prior to its publication. 6 本委員会の評価,学会内での評価,パブリックコメント等が該当すると思います。外部評価の結果,およびそれらがどのようにガイドラインに反映されたかを,追記いただければ幸いです。
14 A procedure for updating the guideline is provided. 7  
DOMAIN 4. CLARITY OF PRESENTATION
15 The recommendations are specific and unambiguous. 7  
16 The different options for management of the condition or health issue are clearly presented. 6 代替案が出しにくい分野であり,エビデンスも限られていると思いますが,さらに記載を増やす努力をお願いします。
17 Key recommendations are easily identifiable. 7 CQ・推奨一覧があり,わかりやすいと思います。目次にも,CQ 番号だけでなく,CQ 文も記載いただくと良いと思います。
DOMAIN 5. APPLICABILITY
18 The guideline describes facilitators and barriers to its application. 5 希少がんであり,検査や治療が可能な施設は限られるのではないでしょうか。施設間格差についても,ご検討,ご記載をお願いいたします。
19 The guideline provides advice and/or tools on how the recommendations can be put into practice. 6 アルゴリズム,CQ・推奨一覧があります。Web 版公開,英語版作成も予定されています。様々なツールを積極的にご活用いただくと,さらに良いでしょう。
20 The potential resource implications of applying the recommendations have been considered. 5 放射線診断領域では,医療経済的観点から過度な検査は避けるべきとの記載や,専門施設への紹介について言及されていて,結構と存じます。他の領域でも,コストやリソース面への記載を,さらに充実させてください。
21 The guideline presents monitoring and/or auditing criteria. 4 Quality indicator など診療プロセスのモニタリングに必要な項目があれば,次回改訂に際し対応してください。
DOMAIN 6. EDITORIAL INDEPENDENCE
22 The views of the funding body have not influenced the content of the guideline. 7  
23 Competing interests of guideline development group members have been recorded and addressed. 6 COI によって投票を棄権した委員に関する記載があり,素晴らしいと思います。各個人のCOI についても,Web 上で適切に公表されることを期待します。
OVERALL GUIDELINE ASSESSMENTE
1 Rate the overall quality of this guideline. 6  
2 I would recommend this guideline for use. yes with modifications  
Notes 前版と比べてかなり改善され,素晴らしいガイドラインになっていると思います。上記に記載されたコメントについて,次版でご検討いただければ,さらに良くなると存じます。

  1. BQ の位置づけ,取り扱い,CQ との違いについて
  2. エビデンス総体の評価についての統一性やlmitation に関する記載の充実
  3. リソースやコストに関する記載の充実
  4. 患者の視点・意向に関する記載の充実
  5. 施設間格差についての検討
  6. SR 結果の公開:いくつかのCQ については,システマティックレビュー(SR)が行われ,フォレストプロット等の図も書かれていらっしゃると伺っています。それらの結果についても公開されると,利用者にとってさらに有用になると思います。HP 上ででも結構ですので,ご検討いただければ幸いです。

(評価日:2021 年10 月4 日)